Failure or Delays in Drug Discovery Research and Increases in R&D Expenses
First written in FY2019. 1 of 2 entries say "Reframed", first in FY2024. Latest entry: FY2024.
Pharma Foods International moved to the "Worse" side of this theme in 2024.
The whole theme swung hardest in 2018: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2024ReframedAnnual report
「If changes in the competitive environment or other factors prevent development and sales from progressing as initially expected, resulting in milestone and royalty income falling short of plan, or if the required profitability cannot be secured even when such income is received, the funds invested in research and development may become unrecoverable, affecting the Group’s financial results.」
In addition to the existing risks of failing to achieve research results and delays in development, the Company specifies risks of development and sales stagnating because of the competitive environment, milestone and royalty income falling short of plan, and insufficient profitability. - FY2019First statedAnnual report
「If expected results cannot be achieved in research and development, leading to the discontinuation of development, or if research and development costs become higher than expected because the development period is prolonged by delays or other factors, the Group’s business development and financial results may be affected.」
The Company discloses as risks the failure to achieve expected results in drug discovery research, the discontinuation or delay of development, and increased costs resulting from prolonged research periods.